Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
This was a very surprising outcome after very strong phase 1b results and the success of competitor Cobenfy in clinical ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
The Associated Press on MSN14d
A promising schizophrenia drug showed mixed results. What does that mean for patients?Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
THURSDAY, Nov. 14, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and ...
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Squibb “announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback